A federal judge in Washington, D.C., ruled against AstraZeneca’s request for a temporary ban on Crestor generics. Unless there is an appeal, the ruling means generic drug manufacturers can now enter the U.S. market, according to a Reuters article.
Crestor reportedly generated more than $5 billion in global sales for AstraZeneca last year.
Sales of the name-brand drug could potentially drop 30 percent as cheaper alternatives become available, according to Bloomberg analyst estimates.
Read the full story